- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Pharmaceutical Technology Europe-02-01-2010
Pharmaceutical Technology Europe
Implications and Opportunities of Applying QbD Principles to Analytical Measurement
February 01, 2010
Analytics
22
2
The authors present two concepts to improve robustness and facilitate continuous improvement in analytical methods.
EU pricing dilemmas
February 01, 2010
Spotlight
22
2
Although representing a huge market, the EU also presents problems that hamper profitability- particularly when it comes to differing price regulations across member states.
Is change good for you?
February 01, 2010
22
2
With the pharmaceutical industry being in a current state of unrest in light of the recent spate of mergers, acquisitions, job cuts, divestments, patent expiries, and so on, we wanted to know how you felt about all these changes that will have directly or indirectly affected you.
Multivariate data analysis easily retrieves insight from a wealth of data
February 01, 2010
Analytics
22
2
Statistics are often viewed as confusing and complicated, but multivariate data analysis (MVA) methods can be used to amass knowledge simply.
Rise of the robots
February 01, 2010
Interview
22
2
Although once used only for large production processes, robotics are now working their way into every aspect of the pharma manufacturing processes.
Your predictions for 2010
February 01, 2010
Survey
22
2
Just before the end of 2009 we gave visitors to our website the opportunity to make some predictions about the 2010 pharma industry… and now it's time for the results.
Commercialising cellular therapies faster
February 01, 2010
Special Feature
22
2
There is much scientific evidence of the early successes of whole cell therapies as disease cures in chronic conditions and disease-modifiers in acute conditions, but limited cases of successfully transferring these discoveries to commercial products or therapies.
Cushioning pharma's fall from the patent precipice
February 01, 2010
Regulation
22
2
Pharma faces imminent expiries of key patents and increasing competition from generics. To protect what they already have, or what they will invent or acquire, companies must give patent protection the attention it deserves.
Biopharmaceuticals: saving the future of our industry
February 01, 2010
Special Feature
22
2
Pharmaceutical Technology Europe discusses some of the latest challenges and innovations that are expected to define the future of pharma.
Achieving site-specific PEGylation
February 01, 2010
Special Feature
22
2
PEGylation has been around for 30 years and it is surprising that it is still widely used given the significant advances that have been made in biopharmaceutical manufacture since then. So why is this the case?
Boosting efficiency and safety by minimising aggregation
February 01, 2010
Special Feature
22
2
Last year, the UK's National Institute for Health and Clinical Excellence (NICE) decided that a new biopharmaceutical cancer drug costing £3000 per month, which could extend a patient's life by 6 months, was not value for money and would not be prescribed in the UK.
Trends and challenges of biopharma manufacturing
February 01, 2010
Special Feature
22
2
The whole pharma/biopharma industry is under pressure to deliver cost-effective new drugs; however, the number of new drug applications is getting lower as the size of investment is increasing.